Format

Send to

Choose Destination
Virology. 2017 Dec;512:194-200. doi: 10.1016/j.virol.2017.09.021. Epub 2017 Oct 3.

Antibody-based immunotherapy of aciclovir resistant ocular herpes simplex virus infections.

Author information

1
Ophtha-Lab, Department of Ophthalmology at St. Franziskus Hospital, Muenster, Germany.
2
Institute for Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
3
University Hospital of Ulm, Institute of Virology, Ulm, Germany.
4
Department of Immune Modulation, University Hospital Erlangen, Erlangen, Germany.
5
University of Bonn Medical Center, Institute of Virology, Bonn, Germany.
6
Department of Viroscience, Erasmus MC, Rotterdam, The Netherlands.
7
Ophtha-Lab, Department of Ophthalmology at St. Franziskus Hospital, Muenster, Germany; University Hospital of Essen, Department of Ophthalmology, Essen, Germany.
8
Institute for Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; Technical University of Munich, Institute of Virology, Munich, Germany.
9
Institute for Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. Electronic address: adalbert.krawczyk@uni-due.de.

Abstract

The increasing incidence of aciclovir- (ACV) resistant strains in patients with ocular herpes simplex virus (HSV) infections is a major health problem in industrialized countries. In the present study, the humanized monoclonal antibody (mAb) hu2c targeting the HSV-1/2 glycoprotein B was examined for its efficacy towards ACV-resistant infections of the eye in the mouse model of acute retinal necrosis (ARN). BALB/c mice were infected by microinjection of an ACV-resistant clinical isolate into the anterior eye chamber to induce ARN and systemically treated with mAb hu2c at 24h prior (pre-exposure prophylaxis) or at 24, 40, and 56h after infection (post-exposure immunotherapy). Mock treated controls and ACV-treated mice showed pronounced retinal damage. Mice treated with mAb hu2c were almost completely protected from developing ARN. In conclusion, mAb hu2c may become a reliable therapeutic option for drug/ACV-resistant ocular HSV infections in humans in order to prevent blindness.

KEYWORDS:

ARN; Aciclovir resistance; HSV; Humanized Anti-HSV-antibody; Infection of the eye

PMID:
28985573
DOI:
10.1016/j.virol.2017.09.021
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center